天风证券研报指出，誉衡药业2025年H1实现归母净利润1.34亿元，同比+7.56%；降本增效继续推进， 成效持续显现。在资产质量方面，公司资产负债率由去年同期的31.66%下降至28.70%，公司资产负债 结构持续优化，抗风险能力继续增强。2025H1公司与兴和制药就佩玛贝特片签订了共同推广协议、与 卫材（中国）就甲钴胺注射液签订了市场推广服务协议。佩玛贝特片作为新一代贝特类药物，具有广阔 市场前景。公司推广佩玛贝特片，将丰富公司的产品管线，有望增加公司的营业收入及利润，增强公司 在心脑血管领域的竞争力；此外，将进一步提升公司的专业化学术推广能力，为未来更多的产品合作奠 定基础。维持"买入"评级。 ...

Group 1 - The report highlights a marginal recovery in China's manufacturing PMI in September, indicating a rebound in production activities, with new orders and export orders showing upward trends [1] - The report suggests three main investment directions based on economic recovery and market liquidity: breakthroughs in technology AI, resonance between domestic and international markets, and the continued rise of undervalued assets [1] - In the A-share market, major indices maintained upward momentum in September, with the ChiNext index rising over 12% and net inflows from southbound funds reaching 172.65 billion yuan [3] Group 2 - The global small nucleic acid drug market is projected to grow at a compound annual growth rate of 26.1%, reaching 46.7 billion USD by 2033, driven by technological advancements and increasing clinical approvals [10] - The report details the clinical progress of small nucleic acid drugs in various therapeutic areas, indicating significant potential for growth in this sector [10] - The report recommends focusing on both international and domestic companies involved in small nucleic acid drugs, highlighting key players in the market [10] Group 3 - The report on Lian Microelectronics indicates a stable revenue growth of 14.18% year-on-year for H1 2025, driven by technological innovation and an integrated supply chain [12] - Despite the revenue growth, the company reported a significant increase in net losses, indicating ongoing profitability challenges [12] - The report emphasizes the importance of capacity expansion and integrated industry chain advantages for the company's stable operations [12] Group 4 - The report on Solon Technology highlights the opportunities created by electrification and domestic substitution trends in the nylon pipeline sector, with potential revenue growth driven by increased demand from electric vehicles [18] - The company has established long-term partnerships with over 30 automotive manufacturers, positioning itself well in the market [18] - Revenue projections for 2025-2027 indicate a growth trajectory, with expected revenues of 1.57 billion, 1.96 billion, and 2.39 billion yuan respectively [18] Group 5 - The report on Yuheng Pharmaceutical shows a decline in revenue by 9.97% in H1 2025, while net profit increased by 7.56%, indicating effective cost management [37] - The company has signed promotional agreements for new drug products, enhancing its market presence and potential revenue streams [37] - The introduction of Pemabet tablets is expected to strengthen the company's product pipeline and competitive position in the cardiovascular sector [38]

Core Insights - The company reported a revenue of 1.1 billion yuan for H1 2025, a decrease of 9.97% year-on-year, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [1] - Cost reduction and efficiency improvement measures are showing positive results, with sales expenses down 31.28% to 294 million yuan and management expenses down 21.58% to 56.75 million yuan [2] - The company signed promotional agreements for Pemabate tablets, which are expected to enhance its product pipeline and competitiveness in the cardiovascular field [3] - Revenue forecasts for 2025-2027 have been adjusted to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while net profit forecasts have been increased to 258 million, 282 million, and 318 million yuan [4] Financial Performance - H1 2025 revenue: 1.1 billion yuan, down 9.97% year-on-year [1] - H1 2025 net profit: 134 million yuan, up 7.56% year-on-year [1] - H1 2025 non-recurring net profit: 107 million yuan, up 13.28% year-on-year [1] Cost Management - Sales expenses decreased from 428 million yuan to 294 million yuan, a reduction of 31.28% [2] - Sales expense ratio fell from 35.06% in H1 2024 to 26.76% [2] - Management expenses decreased from 72.37 million yuan to 56.75 million yuan, a reduction of 21.58% [2] - Asset-liability ratio improved from 31.66% to 28.70% [2] Product Development - The company signed a joint promotion agreement for Pemabate tablets, which have a promising market outlook [3] - Pemabate tablets are the first new selective PPARα modulator approved in China, aimed at lowering triglyceride levels [3] - The promotion of Pemabate tablets is expected to enhance the company's revenue and profit, as well as its academic promotion capabilities [3] Revenue and Profit Forecast - Adjusted revenue forecasts for 2025-2027: 2.364 billion, 2.464 billion, and 2.661 billion yuan [4] - Adjusted net profit forecasts for 2025-2027: 258 million, 282 million, and 318 million yuan [4]

公司报告 | 半年报点评 誉衡药业（002437） 证券研究报告 2025H1 公司与兴和制药就佩玛贝特片签订了共同推广协议、与卫材（中国） 就甲钴胺注射液签订了市场推广服务协议。佩玛贝特片作为新一代贝特类 药物，具有广阔市场前景。 2025 年 4 月，佩玛贝特片（商品名：派龙达）获国家药品监督管理局批准， 在控制饮食的基础上，用于非家族型高甘油三酯血症成年患者，以降低甘 油三酯（TG）水平。佩玛贝特片为全球首个新型高选择性 PPARα调节剂， 主要通过激活 PPARα调节脂质代谢基因表达，实现降低血浆甘油三酯（TG） 水平和提升高密度脂蛋白胆固醇（HDL-C）水平的作用。 公司推广佩玛贝特片，将丰富公司的产品管线，有望增加公司的营业收入 及利润，增强公司在心脑血管领域的竞争力；此外，将进一步提升公司的 专业化学术推广能力，为未来更多的产品合作奠定基础。 盈利预测与投资评级 我们此前对公司 2025-2026 年的收入预测为 25.29/27.99 亿元，对公司 2025-2026 年的归母净利润预测为 2.32/2.68 亿元。考虑到公司 2025H1 收 入略有承压与降本增效持续推进等因素，我们下调公司 ...

Investment Rating - The investment rating for the company is "Add" [1] Core Views - The company has shown continuous improvement in operational efficiency and has good growth potential in its CSO (Contract Sales Organization) business [4] - Key products have maintained stable growth, with significant sales increases in certain categories due to marketing reforms and favorable policy changes [6] - The company has a strong foundation in its CSO business, with ongoing collaborations expected to contribute to revenue growth [6] - Earnings forecasts indicate a slight decline in revenue for 2025, followed by a recovery and growth in subsequent years, with net profit expected to grow steadily [5][6] Financial Summary - The latest closing price is 3.39 CNY, with a one-year high of 4.08 CNY and a low of 1.80 CNY [3] - The current P/E ratio is 31.43, and the P/B ratio is 3.72 [3] - Total shares outstanding are 2.246 billion, with a total market capitalization of 7.613 billion CNY [3] - Revenue for 2024 is projected at 24.41 billion CNY, with a slight decline in 2025 to 24.37 billion CNY, followed by growth to 27.51 billion CNY in 2026 and 30.80 billion CNY in 2027 [5] - Net profit for 2024 is estimated at 2.33 billion CNY, increasing to 2.56 billion CNY in 2025, 2.91 billion CNY in 2026, and 3.28 billion CNY in 2027 [5] - The company’s sales expense ratio has decreased by 8.30 percentage points year-on-year, and management expenses have decreased by 21.58% [6]

Core Viewpoint - Harbin Yuheng Pharmaceutical Co., Ltd. reported a decline in revenue for the first half of 2025, but net profit increased, indicating a mixed performance with potential for future growth through product expansion and cost management [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 1.1 billion yuan, a year-on-year decrease of 9.97% [1]. - Net profit attributable to shareholders was 134 million yuan, an increase of 7.56% year-on-year [1]. - The net profit after deducting non-recurring items was 107 million yuan, up 13.28% year-on-year [1]. - Operating cash flow was 155 million yuan, with a weighted average return on equity of 6.78% [1]. Operational Highlights - The company achieved significant sales growth in key products: - Sales of An Nao Wan/Pian increased by over 30% year-on-year - Revenue from potassium chloride sustained-release tablets also grew by over 30% - The market coverage for Sitagliptin Metformin sustained-release tablets expanded to over 600 terminals [2]. - Management, sales, and financial expenses all saw reductions, with sales expenses down 31.28% to 294 million yuan, management expenses down 21.58% to 56.75 million yuan, and financial expenses down 48.03% to 601,300 yuan [2]. Future Development Strategy - The company plans to enhance asset quality and profitability through: - Continued growth in existing products like Lugu Peptide Injection and multi-vitamin injections - Accelerating sales channel development for new products like Sitagliptin Metformin sustained-release tablets and expanding market reach for new cooperative products [2]. - The company has over 20 projects in development, aiming to obtain approvals for 4 to 6 products this year [2]. - Cost control measures will continue to be a focus, with potential for further reductions in management and sales expenses [2]. Market Expectations - The company expressed optimism about the sales of Pemafibrate tablets, anticipating entry into national negotiations by Q4 2025, which could lead to significant market progress [3]. - The commercial cooperation for Methylcobalamin Injection is expected to contribute to revenue growth [3]. - The Sitagliptin Metformin sustained-release tablets are projected to achieve terminal sales of around 100 million yuan for the year [3]. - The company is exploring international collaborations and has begun exporting products, generating revenue from exports to Central Asia [3]. Investment Outlook - The company is open to investor engagement and is focused on creating value through performance improvement and strategic initiatives [4].

Financial Performance - In the first half of 2025, the company's operating revenue was 11.00 billion CNY, a year-on-year decrease of 9.97% [2] - Net profit attributable to shareholders was 1.34 billion CNY, an increase of 7.56% year-on-year [2] - The net profit after deducting non-recurring gains and losses increased by 13.28% [2] - Operating cash flow was 1.55 billion CNY, with a weighted average return on equity of 6.78% [2] Sales Growth Drivers - Sales of the main product, An Nao Wan/Pian, increased by over 30% year-on-year [3] - Revenue from potassium chloride sustained-release tablets also grew by over 30% [3] - The sales of the drug Siglitin Metformin sustained-release tablets have expanded to over 600 terminals, with expected continued growth [3] Cost Management - Sales expenses decreased by 31.28% to 294 million CNY [3] - Management expenses fell by 21.58% to 56.75 million CNY [3] - Financial expenses reduced from 60.13 million CNY to 48.03 million CNY [3] Future Strategies - Focus on existing product growth, particularly for Luguapeptide injection and multi-vitamin injections [3] - Accelerate the sales channel expansion for Siglitin Metformin sustained-release tablets and explore new markets for Meloxicam tablets [3] - New product Pema Bet tablets expected to launch in September, with high market expectations [3] - The company aims to maintain low levels of financial, management, and sales expenses [3] Market Expectations - Pema Bet tablets projected to enter the national catalog in Q4 2025, with significant market potential [4] - Siglitin Metformin sustained-release tablets expected to achieve sales of approximately 100 million CNY by year-end [4] - An Nao Wan/Pian expected to exceed 10 million boxes in sales, with a target of over 1 billion CNY in the next five years [6] International Expansion - The company has accumulated experience in international cooperation over the past decade and plans to continue exploring new opportunities [7] - Sodium creatine phosphate sales in Central Asia generated 2.46 million CNY in revenue in the first half of 2025 [7] Cost Efficiency - Sales expense ratio has decreased to 26.76% due to refined management and drug procurement policies [8] - Management expense ratio is among the lowest in the industry, with potential for further reduction [8] E-commerce Development - The company has established a professional e-commerce team, expecting online sales to contribute approximately 20% of product revenue [8]

Group 1: Product Performance and Sales Projections - The main product, Injection Multi-Vitamins (12), is expected to achieve a sales growth of 40% in 2024, with sales revenue exceeding 1.1 billion CNY, and a continued growth trend anticipated for 2025 [2][3] - The sales revenue of An Nao Wan/Pills reached 182 million CNY in 2023, an increase of 81.7 million CNY year-on-year, with a projected growth of over 30% in Q1 2025 [3][4] - The company expects significant growth in Chloride Potassium Sustained-Release Tablets this year [6][8] Group 2: Market Position and Competitive Landscape - Injection Multi-Vitamins (12) maintains over 80% market share due to its competitive landscape and brand advantage [2] - The market for Ginkgo Biloba Injection is favorable, with only three competitors expected to increase sales after the current procurement cycle [3] - The company has a stable partnership with Daiichi Sankyo, contributing approximately 10% of total revenue, around 240 million CNY [4][5] Group 3: Sales and Marketing Strategy - The sales expense ratio decreased from 40.69% in the previous year to 32.48% in 2024, with a further reduction to 28.80% in Q1 2025, indicating improved efficiency [8][9] - The company plans to enhance the competitiveness of An Nao Wan/Pills through improved product qualifications and academic promotion [6][8] - Marketing investments will be adjusted based on product lifecycle and profitability, with increased focus on An Nao Wan/Pills post-medical insurance limit removal [9] Group 4: Future Growth and Development Plans - The company aims to expand its product pipeline through new product approvals and potential acquisitions, focusing on innovative and differentiated products [8][9] - There is an emphasis on maintaining steady growth in existing products while exploring new market opportunities [7][8] - The company is committed to cost reduction and efficiency improvements to sustain profitability [8]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].

Core Viewpoint - The announcement highlights a collaboration between Yuheng Pharmaceutical and Xinghe Pharmaceutical for the promotion of Pemabate Tablets, which is expected to enhance Yuheng's product line and competitiveness in the cardiovascular field [1]. Group 1 - Yuheng Pharmaceutical signed a co-promotion agreement with Xinghe Pharmaceutical on May 23, 2025, for Pemabate Tablets [1]. - The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and it can be automatically renewed thereafter [1]. - Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabate Tablets in designated areas and will pay service and promotional support fees [1]. Group 2 - Pemabate Tablets are the world's first novel high-selectivity PPARα modulator, primarily used to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1]. - This collaboration is expected to enrich Yuheng Pharmaceutical's product portfolio and strengthen its competitive position in the cardiovascular sector [1].